TECENTRIQ® (atezolizumab) - Risk of Immune-Related Myositis
Issued March 13, 2019
Issue
As of February 4, 2019, 51 serious and 14 non-serious cases of immune-related myositis have been reported in patients receiving TECENTRIQ treatment including, 4 with a fatal outcome. There were no Canadian cases reported.
Hazard description
Product safety
Get notified of similar recallsEnter your email to receive alerts when new recalls are issued by the same agency.
Subscribed. You'll get an email when new recalls are issued.
RecallTracker